From the Department of Neurology, Children's Hospital, Columbus, OH, USA.
Levetiracetam Prophylaxis in Pediatric Migraine—An Open-Label Study
Article first published online: 19 MAR 2007
Headache: The Journal of Head and Face Pain
Volume 47, Issue 3, pages 427–430, March 2007
How to Cite
Pakalnis, A., Kring, D. and Meier, L. (2007), Levetiracetam Prophylaxis in Pediatric Migraine—An Open-Label Study. Headache: The Journal of Head and Face Pain, 47: 427–430. doi: 10.1111/j.1526-4610.2007.00728.x
- Issue published online: 19 MAR 2007
- Article first published online: 19 MAR 2007
- Accepted for publication December 8, 2006.
Background.—Migraine is common in the pediatric population. Levetiracetam, an anti-epileptic drug, has shown some efficacy in small prospective adult headache studies.
Methods.—We prospectively evaluated levetiracetam in an open-label study in 20 pediatric migraine patients to assess tolerability and efficacy.
Results.—Eighteen of 20 patients had significant reduction in headache frequency. PedMIDAS showed significant decrease in disability scores, side effects were minimal (mild behavioral changes).
Conclusion.—Levetiracetam had some efficacy in reducing migraine frequency and disability. Further larger studies are warranted, possibly utilizing a placebo-controlled design.